Alice T Shaw

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Alice T Shaw
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 368:2385-94. 2013
  2. doi request reprint ALK in lung cancer: past, present, and future
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 31:1105-11. 2013
  3. pmc Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    A T Shaw
    Department of Medicine Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Ann Oncol 24:59-66. 2013
  4. ncbi request reprint Future of early detection of lung cancer: the role of mouse models
    Alice T Shaw
    Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
    Clin Cancer Res 11:4999s-5003s. 2005
  5. doi request reprint Targeting anaplastic lymphoma kinase in lung cancer
    Alice T Shaw
    Thoracic Oncology Center, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 17:2081-6. 2011
  6. pmc Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
  7. pmc ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 19:4273-81. 2013
  8. pmc Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 4:120ra17. 2012
  9. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
  10. pmc ROS1 rearrangements define a unique molecular class of lung cancers
    Kristin Bergethon
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Oncol 30:863-70. 2012

Research Grants

  1. Ras Signaling in Development and Cancer
    Alice Shaw; Fiscal Year: 2007

Collaborators

Detail Information

Publications25

  1. doi request reprint Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Alice T Shaw
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 368:2385-94. 2013
    ..Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown...
  2. doi request reprint ALK in lung cancer: past, present, and future
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 31:1105-11. 2013
    ..In this review, we will discuss the history of this field, current diagnostic and treatment practices, and future challenges and opportunities to advance outcomes for patients with ALK-positive lung cancers...
  3. pmc Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    A T Shaw
    Department of Medicine Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Ann Oncol 24:59-66. 2013
    ....
  4. ncbi request reprint Future of early detection of lung cancer: the role of mouse models
    Alice T Shaw
    Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
    Clin Cancer Res 11:4999s-5003s. 2005
    ..The application of innovative technologies to accurate mouse models promises to accelerate the discovery of new molecular targets and imaging biomarkers for the early detection of lung cancer...
  5. doi request reprint Targeting anaplastic lymphoma kinase in lung cancer
    Alice T Shaw
    Thoracic Oncology Center, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 17:2081-6. 2011
    ..Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the molecular basis for the development of resistance...
  6. pmc Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
    ....
  7. pmc ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 19:4273-81. 2013
    ..Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naïve and crizotinib-resistant cancers...
  8. pmc Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 4:120ra17. 2012
    ....
  9. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  10. pmc ROS1 rearrangements define a unique molecular class of lung cancers
    Kristin Bergethon
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Oncol 30:863-70. 2012
    ..Because little is known about these tumors, we examined the clinical characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement...
  11. doi request reprint Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
    Pasi A Janne
    Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 14:38-47. 2013
    ..We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC...
  12. pmc A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:1602-8. 2012
    ..This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer...
  13. ncbi request reprint Crizotinib and testing for ALK
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Natl Compr Canc Netw 9:1335-41. 2011
    ....
  14. pmc Acquired resistance to crizotinib from a mutation in CD74-ROS1
    Mark M Awad
    Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 368:2395-401. 2013
    ..Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.)...
  15. doi request reprint Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
    Adam S Crystal
    Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 18:4479-81. 2012
    ..The particular ALK fusion expressed may have an impact on protein stability and sensitivity to crizotinib, and this may underlie the heterogeneity in responses observed in the clinic...
  16. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  17. pmc Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Sci Transl Med 3:75ra26. 2011
    ..Collectively, these results deepen our understanding of resistance to EGFR inhibitors and underscore the importance of repeatedly assessing cancers throughout the course of the disease...
  18. pmc Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Proc Natl Acad Sci U S A 108:7535-40. 2011
    ..Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations...
  19. pmc Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
    Justin F Gainor
    From the Massachusetts General Hospital Cancer Center, Boston, MA
    J Clin Oncol 31:3987-96. 2013
    ....
  20. doi request reprint Tyrosine kinase gene rearrangements in epithelial malignancies
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Nat Rev Cancer 13:772-87. 2013
    ..We discuss the clinical outcomes with targeted therapies and explore strategies to discover additional kinases that are activated by chromosomal rearrangements in solid tumours. ..
  21. ncbi request reprint New targets in advanced NSCLC: EML4-ALK
    Adam S Crystal
    Massachusetts General Hospital Cancer Center Center, Boston, MA 02114, USA
    Clin Adv Hematol Oncol 9:207-14. 2011
    ..Here we review the discovery of EML4-ALK, the development of clinical diagnostics for ALK rearrangements, the clinical epidemiology of lung cancers driven by EML4-ALK, and ongoing ALK inhibitor-based clinical trials...
  22. doi request reprint The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer
    Justin F Gainor
    Departments of Medicine, Neurosurgery, Massachusetts General Hospital Cancer Center, Boston, Massachusetts and Department of Medicine, University of California, Irvine, Orange, California
    J Thorac Oncol 8:1570-3. 2013
    ....
  23. pmc Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress
    Alice T Shaw
    Koch Institute for Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 108:8773-8. 2011
    ..Our findings establish the specific antitumor activity of lanperisone and reveal oxidative stress pathways as potential targets in Ras-mediated malignancies...
  24. pmc Novel targets in non-small cell lung cancer: ROS1 and RET fusions
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 18:865-75. 2013
    ..In this review, we summarize the molecular biology, clinical features, detection, and targeting of ROS1 and RET rearrangements in NSCLC. ..
  25. pmc Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
    Alice T Shaw
    Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, and Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston 02114, USA
    Genes Dev 21:694-707. 2007
    ..These findings indicate that in the lung, Sprouty-2 plays a critical role in the regulation of oncogenic K-ras, and implicate counter-regulatory mechanisms in the pathogenesis of Ras-based disease...

Research Grants2

  1. Ras Signaling in Development and Cancer
    Alice Shaw; Fiscal Year: 2007
    ..Aim 3 will test whether induction of Ras/MAPK antagonists plays a role in Ras transformation in vitro and Ras-induced lung tumorigenesis in vivo. ..